Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 125 (final count)
- Started
- Sep 13, 2021
- Main results expected
- May 18, 2026
- Fully finished
- May 18, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose Limiting Toxicities (DLTs) in Part 1A
Measured over: Cycle 1 Day 1 up to just prior to the second dose of study drug at Cycle 2 day 1 (approximately 3 weeks)
Incidence of Dose Limiting Toxicities (DLTs) in Part 1C
Measured over: Cycle 1 Day 1 up to Cycle 3 Day 1 (approximately 6 weeks)
Incidence of treatment-emergent adverse events in Part 1
Measured over: Up to 24 months
Incidence of changes in clinical laboratory abnormalities in Part 1
Measured over: Up to 24 months
Investigator-assessed objective response rate (ORR) per iRECIST in Phase 2
Measured over: Up to 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04896697 · record last updated 2026-09-10 · checked 2026-11-09 15:47 UTC